Leadership Team Archives

Dr Stephen Livesey is a medical doctor, a PhD, biotechnology entrepreneur and Acting Chief Executive Officer of TekCyte. He is also a long-standing member of the company’s Board of Directors. Dr Livesey has a distinguished career spanning medicine, medical research, biotechnology commercialisation and executive leadership, underpinned by a sustained commitment to translating research and innovation into real-world clinical outcomes. He co-founded LifeCell Corporation in the United States, where he was Chief Scientific Officer and Executive Vice President. LifeCell was established through a university technology transfer stemming from Dr Livesey’s invention of a cell and tissue preservation technology. This technology was commercialised through LifeCell, as the product AlloDerm, into multiple types of reconstructive surgeries. LifeCell was ultimately acquired for $US 2.9 billion. He has also served as Chief Scientific Officer and Chief Executive Officer of the Australian Stem Cell Centre, and has held executive, board and research roles across biotechnology, cell therapy and medical research organisations.

Dr Tony Simula is Chief Technology Officer at TekCyte and brings more than 30 years’ experience spanning research and translation, technology development and commercialisation. He has spent much of his career at the interface of science, technology and commercialisation, and has held senior roles across public and private sector research organisations, including Cooperative Research Centres and publicly listed Australian and European companies. Prior to joining TekCyte, he was Manager, Development and Commercialisation at the CRC for Cell Therapy Manufacturing, where he oversaw the progression of technologies from proof-of-concept toward commercial application. Tony brings deep experience and a strong commitment to technology translation, commercialisation and strategic partnering, shaping TekCyte’s technology and commercial direction.

Dr Sue Low (Operations & Quality Lead) supports TekCyte’s operations, quality systems and research coordination, drawing on a strong background in biomaterials development. She completed her PhD in 2008 in dissolvable ocular biomaterials and subsequently worked in related fields focused on plasma surface modification to improve biomaterial compatibility. Sue also has experience in translating medical devices from bench to bedside ready, expanding small scale medical device manufacturing, as well as developing quality systems to ensure consistency across med device manufacture. Her experience across biomaterials, quality systems and medical device development supports TekCyte’s technology translation and commercialisation activities.

Dr Sameer Al-Bataineh is Head of Surface Engineering at TekCyte and brings deep expertise in surface coatings and biomaterials characterisation. He joined the company in 2020 after 14 years of national and international academic research in applied biomaterials. He received his PhD in 2006 for research focused on antimicrobial coatings for biomedical applications. His technical background spans plasma polymerisation, plasma diagnostics, coating process development, surface characterisation and data analysis, supporting TekCyte’s technology development and commercialisation activities.

Share This